Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SYRS

Syros Pharmaceuticals Inc.

Sep 20 • 04:00PM ET

1.95

Dollar change -0.03
Percentage change -1.52	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-4.30	Insider Own	26.35%	Shs Outstand	26.45M	Perf Week	0.00%
Market Cap	52.12M	Forward P/E	-	EPS next Y	-2.71	Insider Trans	2.24%	Shs Float	19.69M	Perf Month	14.04%
Income	-131.56M	PEG	-	EPS next Q	-0.68	Inst Own	56.22%	Short Float	4.86%	Perf Quarter	-65.05%
Sales	4.15M	P/S	12.56	EPS this Y	64.31%	Inst Trans	85.92%	Short Ratio	3.13	Perf Half Y	-69.24%
Book/sh	-0.24	P/B	-	EPS next Y	-30.50%	ROA	-91.46%	Short Interest	0.96M	Perf Year	-50.26%
Cash/sh	2.95	P/C	0.66	EPS next 5Y	-	ROE	-393.39%	52W Range	1.43 - 8.17	Perf YTD	-74.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.16%	ROI	-253.91%	52W High	-76.13%	Beta	1.58
Dividend TTM	-	Quick Ratio	3.46	Sales past 5Y	128.79%	Gross Margin	62.39%	52W Low	36.36%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.46	EPS Y/Y TTM	22.30%	Oper. Margin	-2835.68%	RSI (14)	39.57	Volatility	9.66% 9.18%
Employees	68	Debt/Eq	-	Sales Y/Y TTM	-53.52%	Profit Margin	-3171.70%	Recom	1.00	Target Price	8.75
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	54.27%	Payout	-	Rel Volume	0.68	Prev Close	1.98
Sales Surprise	-100.00%	EPS Surprise	23.12%	Sales Q/Q	-100.00%	Earnings	Jul 31 BMO	Avg Volume	306.17K	Price	1.95
SMA20	15.86%	SMA50	-45.76%	SMA200	-63.46%	Trades		Volume	207,078	Change	-1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-20	Upgrade	H.C. Wainwright	Neutral → Buy	$11 → $15
Sep-22-20	Initiated	Alliance Global Partners	Buy	$18
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Mar-08-19	Resumed	JMP Securities	Mkt Outperform	$18
Feb-14-19	Resumed	Oppenheimer	Outperform	$13
Nov-05-18	Upgrade	ROTH Capital	Neutral → Buy
Mar-13-18	Reiterated	Wedbush	Outperform	$11 → $13
Oct-31-17	Resumed	Piper Jaffray	Overweight	$30
Oct-23-17	Initiated	ROTH Capital	Neutral	$15
Aug-10-17	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Sep-12-24 07:00PM	Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com) +24.20%
07:00PM	Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com)
Aug-27-24 07:00AM	Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences (Business Wire) -5.99%
Aug-14-24 10:19AM	Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination (Zacks) -15.89%
09:35AM	Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
09:41AM	Loading…
Aug-13-24 09:41AM	Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome (Benzinga) -61.68%
09:13AM	Syros stock craters after Phase II AML trial termination due to inefficacy (Pharmaceutical Technology)
Aug-12-24 04:15PM	Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial (Business Wire)
Aug-05-24 09:55AM	Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:30AM	Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Jul-24-24 07:00AM	Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 (Business Wire)
Jul-17-24 11:24AM	Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why (Zacks)
08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-13-24 07:00AM	Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression (Business Wire) +7.41%
May-15-24 03:03AM	Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
01:14AM	Loading…
01:14AM	Q1 2024 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 10:52AM	SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +7.31%
07:30AM	Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
May-07-24 09:00AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
07:00AM	Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 (Business Wire)
May-01-24 10:01AM	Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-24 09:49AM	Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML (Zacks)
08:30AM	Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-09-24 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression (Business Wire) +22.22%
Apr-02-24 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.04% +7.44%
Mar-28-24 10:06AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.39%
Mar-27-24 11:53AM	SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.56%
07:30AM	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Mar-25-24 07:00AM	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial (Business Wire)
Mar-20-24 07:00AM	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 (Business Wire)
07:00AM	Loading…
Feb-27-24 07:00AM	Syros to Participate in TD Cowen 44th Annual Health Care Conference (Business Wire)
Jan-31-24 04:00PM	3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential (InvestorPlace)
Jan-19-24 10:43AM	Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why (Zacks)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice (Zacks) -6.09%
Jan-17-24 08:50AM	Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-16-24 12:00PM	What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know (Zacks)
Jan-11-24 08:48AM	Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick (Zacks)
Jan-08-24 07:00AM	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene (Business Wire)
Jan-03-24 11:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals (GuruFocus.com) -9.95%
Dec-19-23 07:27AM	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +30.93%
Dec-07-23 09:44AM	Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene (Zacks) +15.92%
Dec-06-23 07:00AM	Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine (Business Wire) +42.55%
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-21-23 07:30AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
Nov-15-23 01:08PM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript (Insider Monkey) +11.76%
Nov-14-23 07:30AM	Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-23 07:30AM	Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire) +5.36%
Oct-02-23 08:45AM	Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company (Business Wire) -18.73%
Sep-07-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 09:49PM	Q2 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Aug-01-23 07:30AM	Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-27-23 06:29AM	The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet (American City Business Journals)
Jul-21-23 05:40PM	Pfizer to end license deal with Syros for blood disorder therapies (Reuters)
Jul-05-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-08-23 07:30AM	Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference (Business Wire)
Jun-01-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-25-23 05:05PM	Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting (Business Wire) -5.06%
08:44AM	One Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \ (Simply Wall St.)
May-13-23 10:15AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 10:08PM	Q1 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +10.29%
08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
May-09-23 07:00AM	Syros to Present at JMP Securities 2023 Life Sciences Conference (Business Wire)
May-07-23 08:40PM	ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? (Zacks)
May-03-23 07:30AM	Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (Business Wire)
May-02-23 07:00AM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.95%
Mar-06-23 09:48AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 07:08AM	Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Mar-02-23 10:02PM	Q4 2022 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (Business Wire)
Feb-28-23 07:30AM	Syros to Participate in Upcoming Investor Conferences in March (Business Wire)
Feb-23-23 07:30AM	Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 (Business Wire)
Feb-09-23 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.61%
Feb-01-23 09:43AM	Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jan-26-23 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome (Business Wire)
Jan-09-23 07:00AM	Syros Announces Clinical Updates and 2023 Strategic Priorities (Business Wire)
Dec-23-22 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-22 06:47AM	One Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous year (Simply Wall St.) -7.73%
Dec-12-22 07:30AM	Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS (Business Wire) +5.04%
Dec-10-22 10:00AM	Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial (Business Wire)
Dec-05-22 07:00AM	Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 (Business Wire)
Nov-22-22 07:30AM	Syros to Participate at Piper Sandler 34th Annual Healthcare Conference (Business Wire)
Nov-14-22 08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.04%
07:30AM	Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-22 07:30AM	Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (Business Wire)
Nov-04-22 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-03-22 09:01AM	Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting (Business Wire)
Oct-05-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-22 12:00PM	Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.88%
Sep-16-22 04:05PM	Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement (Business Wire) -17.27%
Sep-15-22 04:13PM	Syros and Tyme Technologies Announce Stockholder Approval of Merger (GlobeNewswire)
Sep-14-22 01:26PM	Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug (Zacks) -7.56%
Sep-13-22 04:01PM	Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer (Business Wire)

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chee Conley	President & CEO	Sep 11 '24	Buy	1.71	50,000	85,420	122,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 12 '24	Buy	1.68	45,344	76,006	124,552	Sep 12 05:00 PM
Chee Conley	President & CEO	Sep 10 '24	Buy	1.51	50,000	75,260	72,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 10 '24	Buy	1.55	35,363	54,788	59,915	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 11 '24	Buy	1.58	19,293	30,446	79,208	Sep 12 05:00 PM
Young Richard A	Director	Jun 28 '24	Sale	5.12	34,837	178,365	8,000	Jul 02 04:15 PM
Roth David	Chief Medical Officer	Apr 03 '24	Sale	4.95	10,451	51,732	0	Apr 05 04:30 PM
Roth David	Chief Medical Officer	Apr 02 '24	Sale	4.98	150	747	10,451	Apr 02 04:58 PM
AKKARAJU SRINIVAS	Director	Dec 21 '23	Buy	4.42	904,977	3,999,998	1,786,427	Dec 26 05:24 PM
Roth David	Chief Medical Officer	Dec 12 '23	Sale	4.95	6,287	31,121	0	Dec 14 04:24 PM
Roth David	Chief Medical Officer	Dec 06 '23	Sale	3.95	6,287	24,834	6,287	Dec 08 04:23 PM

Open in Screener

OMGA

Omega Therapeutics Inc

Sep 20 • 04:00PM ET

1.37

Dollar change -0.05
Percentage change -3.52	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

OMGA Omega Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWC BTEC

Index	-	P/E	-	EPS (ttm)	-1.43	Insider Own	62.93%	Shs Outstand	55.14M	Perf Week	3.01%
Market Cap	75.57M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.00%	Shs Float	20.45M	Perf Month	-13.29%
Income	-78.90M	PEG	-	EPS next Q	-0.28	Inst Own	30.35%	Short Float	27.22%	Perf Quarter	-43.62%
Sales	6.31M	P/S	11.98	EPS this Y	37.06%	Inst Trans	0.24%	Short Ratio	17.01	Perf Half Y	-61.62%
Book/sh	0.48	P/B	2.88	EPS next Y	20.30%	ROA	-39.72%	Short Interest	5.57M	Perf Year	-53.95%
Cash/sh	0.84	P/C	1.64	EPS next 5Y	-	ROE	-129.15%	52W Range	1.22 - 6.30	Perf YTD	-54.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.08%	ROI	-57.43%	52W High	-78.25%	Beta	1.86
Dividend TTM	-	Quick Ratio	2.19	Sales past 5Y	347.21%	Gross Margin	3.80%	52W Low	12.30%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	2.19	EPS Y/Y TTM	35.59%	Oper. Margin	-1277.05%	RSI (14)	44.69	Volatility	7.54% 6.08%
Employees	94	Debt/Eq	4.83	Sales Y/Y TTM	142.38%	Profit Margin	-1249.54%	Recom	1.17	Target Price	10.33
Option/Short	Yes / Yes	LT Debt/Eq	4.23	EPS Q/Q	45.15%	Payout	-	Rel Volume	0.30	Prev Close	1.42
Sales Surprise	123.20%	EPS Surprise	17.88%	Sales Q/Q	181.16%	Earnings	Aug 06 BMO	Avg Volume	327.27K	Price	1.37
SMA20	-0.72%	SMA50	-13.83%	SMA200	-47.64%	Trades		Volume	99,565	Change	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-24	Initiated	Raymond James	Outperform	$12
May-25-23	Resumed	Jefferies	Buy	$18 → $15
Dec-08-22	Initiated	H.C. Wainwright	Buy	$11
Sep-23-22	Initiated	Chardan Capital Markets	Buy	$12

Sep-17-24 07:00AM	Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications (GlobeNewswire)
Aug-14-24 07:00AM	Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research (GlobeNewswire)
Aug-06-24 01:53PM	OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +6.82%
08:10AM	Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
06:30AM	Loading…
06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Jul-29-24 07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire) -5.26%
Jun-24-24 07:00AM	Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors (GlobeNewswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
May-30-24 07:00AM	Omega Therapeutics To Participate In Two Upcoming Investor Conferences (GlobeNewswire)
May-29-24 07:00AM	Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer (GlobeNewswire) -6.16%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 07:00AM	Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers (GlobeNewswire)
02:52PM	Loading…
May-06-24 02:52PM	OMGA Stock Earnings: Omega Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) -11.63%
08:10AM	Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-25-24 10:02AM	Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-23-24 07:00AM	Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-17-24 09:55AM	Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) +6.02%
Apr-09-24 07:00AM	Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control (GlobeNewswire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Apr-03-24 12:00PM	Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-28-24 11:54PM	OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -12.33%
10:25AM	Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
09:15AM	Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update (GlobeNewswire)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Mar-06-24 07:00AM	Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire) +5.47%
Jan-09-24 11:01PM	The 3 Best Biotech Stocks to Buy in January 2024 (InvestorPlace) +19.71%
08:44AM	Loading…
08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-05-24 12:55PM	Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk (Zacks) -17.40%
Jan-04-24 06:08PM	Why Novo Nordisk Stock Crushed the Market Today (Motley Fool) +94.69%
04:01PM	Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity (Investor's Business Daily)
10:02AM	Novo Nordisk enters research partnerships with biotech firms (Yahoo Finance Video)
08:20AM	Why Is Omega Therapeutics (OMGA) Stock Up 111% Today? (InvestorPlace)
06:00AM	Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms (Reuters)
05:59AM	Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases (GlobeNewswire)
Jan-02-24 04:05PM	Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.08%
Dec-04-23 04:00PM	Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire)
Nov-20-23 04:00PM	Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) -6.54%
Nov-13-23 07:00AM	Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis (GlobeNewswire)
Nov-09-23 07:00AM	Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -5.06%
Nov-07-23 04:00PM	Omega Therapeutics to Participate in The Jefferies London Healthcare Conference (GlobeNewswire)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-31-23 07:00AM	Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller (GlobeNewswire) -7.43%
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire) -11.63%
Oct-16-23 07:00AM	Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC (GlobeNewswire)
Oct-11-23 04:00PM	Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting 2023 (GlobeNewswire) -12.93% -6.77%
Oct-04-23 04:00PM	Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +10.14%
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -12.09%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-26-23 07:00AM	Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial (GlobeNewswire) -23.17%
Sep-25-23 04:00PM	Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial on September 26 (GlobeNewswire)
Sep-21-23 04:00PM	Omega Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +5.37%
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Aug-29-23 07:00AM	Omega Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) +8.29%
Aug-05-23 08:05AM	Omega Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Aug-03-23 05:15PM	Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jul-20-23 07:39AM	Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why (Zacks) +8.85%
Jul-18-23 09:43AM	Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data (Zacks)
Jul-12-23 07:00AM	Omega Therapeutics Appoints Chris Schade to its Board of Directors (GlobeNewswire) +12.25%
Jul-03-23 11:20AM	Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune (Zacks) -14.11%
Jun-22-23 09:18AM	Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate (Zacks)
Jun-14-23 11:48AM	Recursion (RXRX) Up on Completing REC-994 Study Enrollment (Zacks)
Jun-08-23 11:49AM	Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001 (Zacks)
Jun-06-23 12:13PM	Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails (Zacks)
Jun-01-23 07:00AM	Omega Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -5.14%
May-31-23 08:30AM	Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors (GlobeNewswire)
07:00AM	Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting (GlobeNewswire)
May-25-23 09:55AM	Wall Street Analysts See a 59.64% Upside in Omega Therapeutics, Inc. (OMGA): Can the Stock Really Move This High? (Zacks) -9.24%
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire)
May-10-23 07:34AM	Investors in Omega Therapeutics (NASDAQ:OMGA) have seen impressive returns of 177% over the past year (Simply Wall St.) -5.46%
May-09-23 09:55AM	Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 48.23%: Read This Before Placing a Bet (Zacks)
May-04-23 08:35AM	Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-27-23 07:00AM	Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting (GlobeNewswire) +9.74%
Apr-13-23 06:33AM	Private equity firms account for 53% of Omega Therapeutics, Inc.'s (NASDAQ:OMGA) ownership, while institutions account for 32% (Simply Wall St.) +6.44%
Apr-06-23 04:01AM	Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains? (Zacks) +7.79%
Mar-30-23 07:00AM	Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma (GlobeNewswire)
Mar-17-23 03:35AM	Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last? (Zacks) +25.22%
Mar-03-23 05:01AM	When Can We Expect A Profit From Omega Therapeutics, Inc. (NASDAQ:OMGA)? (Simply Wall St.)
Mar-01-23 08:35AM	Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-23 07:00AM	Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock (GlobeNewswire)
Feb-10-23 04:11AM	Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains? (Zacks) -10.08%
Jan-17-23 07:00AM	Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (GlobeNewswire) -12.60%
Dec-08-22 01:24PM	Omega Therapeutics Could Offer 'Intriguing' Liver Cancer Drug, Analyst Says (Benzinga)
Nov-28-22 09:55AM	Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a Bet (Zacks)
Nov-17-22 07:00AM	Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-15-22 07:00AM	Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work (PR Newswire)
Nov-11-22 09:55AM	Wall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to Trade (Zacks) +16.57%
Nov-10-22 05:57AM	Shareholders in Omega Therapeutics (NASDAQ:OMGA) have lost 79%, as stock drops 13% this past week (Simply Wall St.) +9.15%
Nov-08-22 07:00AM	Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
Nov-03-22 07:00AM	Omega Therapeutics to Participate in the Jefferies London Healthcare Conference (PR Newswire)

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

SYRS

Syros Pharmaceuticals Inc.

OMGA

Omega Therapeutics Inc

Upgrade your FINVIZ experience